PSPer Svedenhag

Per Svedenhag

*This is an algorithmically generated author record based on publicly available information.

Per Svedenhag has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Startups Driving Artificial Intelligence Into Clinical Dermatology

    by Dominique Du Crest, Benjamin Miguel Monteagudo, Stanislas Vandier, Mullarkey Dan, Svedenhag Per, Jon Friis, Monisha Madhumita, Lilit Garibyan, Tu‐Anh Duong, Merete Haedersdal, et al.

    Artificial intelligence (AI) is rapidly transitioning from innovation to routine clinical application in dermatology. This review examines how AI‐enabled technologies are being developed and integrated across diverse clinical purposes and workflows. Using a structured assessment template, we analyzed international initiatives and industry‐led innovations to identify the clinical gaps addressed, underlying technologies, use cases, and real‐world implementation experiences. The resulting profiles highlight a broad spectrum of AI‐driven and enabled applications, including wearable sensors with haptic feedback for objective symptom monitoring; patient‐initiated teledermatology platforms that enhance access to specialist care; non‐invasive diagnostic tools employing impedance spectroscopy; autonomous triage systems for dermoscopic lesions; and sensors that combine intrinsic skin biomarkers with exposome analytics. Collectively, these technologies illustrate a shift toward generating objective, reproducible data that complement clinical assessment, facilitating earlier detection, streamlined referrals, and longitudinal, patient‐centred care. While validation studies are encouraging, regulatory and reimbursement pathways, along with limited data diversity, are current hurdles to a more large‐scale adoption. By synthesizing insights from these technological approaches, this review aims to provide dermatologists with a pragmatic overview of AI‐driven health technologies as emerging, evidence‐based, commercial initiatives that may shape the future of dermatologic care.

  • Open Access

    New regulation of medical devices in the EU: impact in dermatology

    by Josep Malvehy, Robert Ginsberg, Laura Sampietro-Colom, Joan Ficapal, Marc Combalia, Per Svedenhag

    Medical device (MD) is a broad term that encompasses products ranging from, for example, examination gloves to digital dermoscopy systems; all of which are regulated by a new regulatory framework in the EU from May 2021. The new Medical Device Regulation (MDR) (Regulation EU 2017/745) will have a significant effect on suppliers of MD and will have subsequent effects also for dermatologists and other clinicians. Medical device software and apps are reclassified leading to more stringent requirements on documentation within, e.g. clinical evidence, as well as regulatory authority control. The changes will likely have positive effects on quality, to the benefit of patients. There will, however, be implications affecting the availability and support of existing devices and the introduction of new devices, as well as a likely price increase due to the higher costs for suppliers. Dermatologists, other clinicians and administrators need to be aware of the effects of MDR to ensure that existing devices and new purchases can be used as planned. Specifically, clinicians need to be aware of the following: (i) improved quality of MD and follow‐up of incidents can be expected. (ii) Only ‘non‐significant’ updates will be permitted after May 2021 to many existing systems and devices unless approved under the new MDR. (iii) Existing devices that do not achieve approval under the new regulation will no longer be manufactured after May 2024. (iv) New products and methods will take longer time to be approved and available. (v) Prices will likely increase. (vi) Suppliers of products that do not fulfil the new regulation will disappear, and the availability of consumables, spare parts or upgrades might be discontinued. (vii) A trend to oligopoly may appear in the market. It is therefore important to check with your suppliers as to how and when they will adhere to the new MDR regulation.